{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T19:30:41Z","timestamp":1784921441143,"version":"3.55.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.clml.2023.11.006","type":"journal-article","created":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T17:59:57Z","timestamp":1701107997000},"page":"e88-e95","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Multiparametric Flow Cytometry in the Evaluation of Plasma Cell Proliferative Disorders: Current Paradigms for Clinical Practice"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5364-4086","authenticated-orcid":false,"given":"Ritu","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragan","family":"Jevremovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smith J.","family":"Mathew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.clml.2023.11.006_bib0001","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.clml.2023.11.006_bib0002","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells","volume":"110","author":"P\u00e9rez-Persona","year":"2007","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2023.11.006_bib0003","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/ijlh.13887","article-title":"Effect of the sequence of pull of bone marrow aspirates on plasma cell quantification in plasma cell proliferative disorders","volume":"44","author":"Jain","year":"2022","journal-title":"Int J Lab Hematol"},{"issue":"6","key":"10.1016\/j.clml.2023.11.006_bib0004","first-page":"1655","article-title":"Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma","volume":"152","author":"Ocqueteau","year":"1998","journal-title":"Am J Pathol"},{"issue":"1","key":"10.1016\/j.clml.2023.11.006_bib0005","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1365-2141.2009.07929.x","article-title":"Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells","volume":"148","author":"P\u00e9rez-Persona","year":"2010","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.clml.2023.11.006_bib0006","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41408-018-0077-4","article-title":"Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria","volume":"8","author":"Lakshman","year":"2018","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1016\/j.clml.2023.11.006_bib0007","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-020-00366-3","article-title":"International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)","volume":"10","author":"Mateos","year":"2020","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1016\/j.clml.2023.11.006_bib0008","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1038\/leu.2013.166","article-title":"A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control","volume":"27","author":"Paiva","year":"2013","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.clml.2023.11.006_bib0009","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41408-019-0176-x","article-title":"Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature","volume":"9","author":"Rodr\u00edguez-Otero","year":"2019","journal-title":"Blood Cancer J"},{"issue":"16","key":"10.1016\/j.clml.2023.11.006_bib0010","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1200\/JCO.22.01916","article-title":"Definition and clinical significance of the monoclonal gammopathy of undetermined significance-like phenotype in patients with monoclonal gammopathies","volume":"41","author":"Burgos","year":"2023","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clml.2023.11.006_bib0011","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/ajh.23201","article-title":"Trends and outcomes of modern staging of solitary plasmacytoma of bone","volume":"87","author":"Warsame","year":"2012","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.clml.2023.11.006_bib0012","first-page":"1195","article-title":"The significance of CD319 and CD269 in the detection of immunophenotyping and minimal residual disease in multiple myeloma patients","volume":"29","author":"Chu","year":"2021","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"2","key":"10.1016\/j.clml.2023.11.006_bib0013","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/ijlh.13992","article-title":"Utility of CD229 as novel marker in measurable residual disease assessment in multiple myeloma: an evidence-based approach","volume":"45","author":"Rai","year":"2023","journal-title":"Int J Lab Hematol"},{"issue":"3","key":"10.1016\/j.clml.2023.11.006_bib0014","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3324\/haematol.11080","article-title":"Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders","volume":"93","author":"Rawstron","year":"2008","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.clml.2023.11.006_bib0015","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/cyto.b.21228","article-title":"Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting","volume":"90","author":"Arroz","year":"2016","journal-title":"Cytometry B Clin Cytom"},{"issue":"1","key":"10.1016\/j.clml.2023.11.006_bib0016","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/ajcp\/aqac129","article-title":"Graded depth of response and neoplastic plasma cell index as indicators of survival outcomes in patients with multiple myeloma following autologous stem cell transplant","volume":"159","author":"Das","year":"2023","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"10.1016\/j.clml.2023.11.006_bib0017","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1309\/AJCP1GYI7EHQYUYK","article-title":"Flow cytometric immunophenotyping and minimal residual disease analysis in multiple myeloma","volume":"132","author":"Gupta","year":"2009","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"10.1016\/j.clml.2023.11.006_bib0018","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/cyto.b.22068","article-title":"Relevance of polyclonal plasma cells and post-therapy immunomodulation in measurable residual disease assessment in multiple myeloma","volume":"102","author":"Das","year":"2022","journal-title":"Cytometry B Clin Cytom"},{"issue":"4","key":"10.1016\/j.clml.2023.11.006_bib0019","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/cyto.b.22062","article-title":"Flow cytometric immunophenotyping of plasma cells across the spectrum of plasma cell proliferative disorders: a fresh insight with pattern-based recognition","volume":"102","author":"Das","year":"2022","journal-title":"Cytometry B Clin Cytom"},{"issue":"1","key":"10.1016\/j.clml.2023.11.006_bib0020","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis","volume":"3","author":"Munshi","year":"2017","journal-title":"JAMA Oncol"},{"issue":"23","key":"10.1016\/j.clml.2023.11.006_bib0021","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.clml.2023.11.006_bib0022","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clml.2023.11.006_bib0023","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/cyto.b.21268","article-title":"Regulatory perspective on minimal residual disease flow cytometry testing in multiple myeloma","volume":"90","author":"Gormley","year":"2016","journal-title":"Cytometry B Clin Cytom"},{"issue":"19","key":"10.1016\/j.clml.2023.11.006_bib0024","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.1158\/1078-0432.CCR-21-1059","article-title":"Minimal residual disease in myeloma: application for clinical care and new drug registration","volume":"27","author":"Anderson","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2023.11.006_bib0025","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/archinte.133.5.813","article-title":"Plasma cell leukemia. Report on 17 cases","volume":"133","author":"Kyle","year":"1974","journal-title":"Arch Intern Med"},{"issue":"2","key":"10.1016\/j.clml.2023.11.006_bib0026","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00277-014-2211-0","article-title":"Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patients","volume":"94","author":"An","year":"2015","journal-title":"Ann Hematol"},{"issue":"6","key":"10.1016\/j.clml.2023.11.006_bib0027","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.3324\/haematol.2016.158303","article-title":"Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition","volume":"102","author":"Granell","year":"2017","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.clml.2023.11.006_bib0028","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-018-0140-1","article-title":"Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma","volume":"8","author":"Ravi","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2023.11.006_bib0029","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41408-021-00587-0","article-title":"Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage","volume":"11","author":"Fern\u00e1ndez de Larrea","year":"2021","journal-title":"Blood Cancer J"},{"issue":"7","key":"10.1016\/j.clml.2023.11.006_bib0030","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1200\/JCO.22.01226","article-title":"More than 2% of circulating tumor plasma cells defines plasma cell leukemia-like multiple myeloma","volume":"41","author":"Jelinek","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2023.11.006_bib0031","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1080\/16078454.2021.1948208","article-title":"Prognostic value of circulating clonal plasma cells in newly diagnosed multiple myeloma","volume":"26","author":"Han","year":"2021","journal-title":"Hematology"},{"issue":"27","key":"10.1016\/j.clml.2023.11.006_bib0032","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1200\/JCO.21.01365","article-title":"Circulating tumor cells for the staging of patients with newly diagnosed transplant-eligible multiple myeloma","volume":"40","author":"Garc\u00e9s","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clml.2023.11.006_bib0033","doi-asserted-by":"crossref","first-page":"641","DOI":"10.3109\/10428194.2011.627481","article-title":"Circulating plasma cells predict the outcome of relapsed or refractory multiple myeloma","volume":"53","author":"Peceliunas","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"27","key":"10.1016\/j.clml.2023.11.006_bib0034","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1200\/JCO.21.01393","article-title":"High levels of circulating tumor plasma cells as a key hallmark of aggressive disease in transplant-eligible patients with newly diagnosed multiple myeloma","volume":"40","author":"Bertamini","year":"2022","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.clml.2023.11.006_bib0035","doi-asserted-by":"crossref","first-page":"5668","DOI":"10.1200\/JCO.2005.03.159","article-title":"Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance","volume":"23","author":"Kumar","year":"2005","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clml.2023.11.006_bib0036","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/leu.2012.237","article-title":"High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma","volume":"27","author":"Bianchi","year":"2013","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2023.11.006_bib0037","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/leu.2016.205","article-title":"Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression","volume":"31","author":"Gonsalves","year":"2017","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.clml.2023.11.006_bib0038","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41408-018-0153-9","article-title":"Next generation flow for minimally invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)","volume":"8","author":"Sanoja-Flores","year":"2018","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.clml.2023.11.006_bib0039","first-page":"2736","article-title":"Blood-based risk stratification for pre-malignant and symptomatic plasma cell neoplasms to improve patient management","volume":"11","author":"Vasco-Mogorr\u00f3n","year":"2021","journal-title":"Am J Cancer Res"},{"issue":"12","key":"10.1016\/j.clml.2023.11.006_bib0040","doi-asserted-by":"crossref","first-page":"5920","DOI":"10.1002\/cam4.1840","article-title":"Expression of CD81 and CD117 in plasma cell myeloma and the relationship to prognosis","volume":"7","author":"Chen","year":"2018","journal-title":"Cancer Med"},{"issue":"4","key":"10.1016\/j.clml.2023.11.006_bib0041","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/leu.2017.320","article-title":"Prognostic value of antigen expression in multiple myeloma: a PETHEMA\/GEM study on 1265 patients enrolled in four consecutive clinical trials","volume":"32","author":"Arana","year":"2018","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.clml.2023.11.006_bib0042","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.4049\/jimmunol.1100016","article-title":"CD28 expressed on malignant plasma cells induces a prosurvival and immunosuppressive microenvironment","volume":"187","author":"Nair","year":"2011","journal-title":"J Immunol"},{"issue":"16","key":"10.1016\/j.clml.2023.11.006_bib0043","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1200\/JCO.2007.15.4120","article-title":"Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA\/GEM cooperative study groups on patients uniformly treated with high-dose therapy","volume":"26","author":"Mateo","year":"2008","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clml.2023.11.006_bib0044","first-page":"547","article-title":"Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma","volume":"89","author":"Moreau","year":"2004","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.clml.2023.11.006_bib0045","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/ejh.13046","article-title":"Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis","volume":"100","author":"Pick","year":"2018","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2023.11.006_bib0046","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.leukres.2016.03.003","article-title":"The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma","volume":"44","author":"Gonsalves","year":"2016","journal-title":"Leuk Res"},{"issue":"4","key":"10.1016\/j.clml.2023.11.006_bib0047","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1309\/74R4TB90BUWH27JX","article-title":"Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma","volume":"121","author":"Lin","year":"2004","journal-title":"Am J Clin Pathol"},{"issue":"12","key":"10.1016\/j.clml.2023.11.006_bib0048","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1038\/sj.leu.2401211","article-title":"The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma","volume":"12","author":"Pellat-Deceunynck","year":"1998","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.clml.2023.11.006_bib0049","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1159\/000489483","article-title":"CD56 expression is an important prognostic factor in multiple myeloma even with bortezomib induction","volume":"139","author":"Skerget","year":"2018","journal-title":"Acta Haematol"},{"issue":"11","key":"10.1016\/j.clml.2023.11.006_bib0050","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12032-020-01423-4","article-title":"The clinical significance of CD49e and CD56 for multiple myeloma in the novel agents era","volume":"37","author":"Okura","year":"2020","journal-title":"Med Oncol"},{"issue":"9","key":"10.1016\/j.clml.2023.11.006_bib0051","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1080\/07357907.2021.1964521","article-title":"Prognostic relevance of concordant expression CD69 and CD56 in response to bortezomib combination therapy in multiple myeloma patients","volume":"39","author":"ElMenshawy","year":"2021","journal-title":"Cancer Invest"},{"issue":"1","key":"10.1016\/j.clml.2023.11.006_bib0052","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000493568","article-title":"Multiparameter flow cytometry identification of neoplastic subclones: a new biomarker in monoclonal gammopathy of undetermined significance and multiple myeloma","volume":"141","author":"Tar\u00edn","year":"2019","journal-title":"Acta Haematol"},{"issue":"1","key":"10.1016\/j.clml.2023.11.006_bib0053","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1046\/j.1365-2141.2003.04260.x","article-title":"CD27 is heterogeneously expressed in multiple myeloma: low CD27 expression in patients with high-risk disease","volume":"121","author":"Guikema","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2023.11.006_bib0054","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108363","article-title":"CD27 antigen negative expression indicates poor prognosis in newly diagnosed multiple myeloma","volume":"213","author":"Chu","year":"2020","journal-title":"Clin Immunol"},{"issue":"3","key":"10.1016\/j.clml.2023.11.006_bib0055","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1046\/j.1365-2141.2003.04783.x","article-title":"CD27-triggering on primary plasma cell leukaemia cells has anti-apoptotic effects involving mitogen activated protein kinases","volume":"124","author":"Guikema","year":"2004","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.clml.2023.11.006_bib0056","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1158\/1078-0432.CCR-04-1489","article-title":"Genetic abnormalities and patterns of antigenic expression in multiple myeloma","volume":"11","author":"Mateo","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2023.11.006_bib0057","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1061438","article-title":"CD20 expression: a risk stratification factor for newly diagnosed multiple myeloma with t(11;14)","volume":"12","author":"Jian","year":"2022","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.clml.2023.11.006_bib0058","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/ajh.25391","article-title":"Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi-parametric flow cytometry method","volume":"94","author":"Sidana","year":"2019","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.clml.2023.11.006_bib0059","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/cyto.a.22803","article-title":"A novel and easy FxCycle\u2122 violet based flow cytometric method for simultaneous assessment of DNA ploidy and six-color immunophenotyping","volume":"89","author":"Tembhare","year":"2016","journal-title":"Cytometry A"},{"issue":"8","key":"10.1016\/j.clml.2023.11.006_bib0060","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1182\/blood.V97.8.2522","article-title":"A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is a marker for early disease progression and death","volume":"97","author":"Steensma","year":"2001","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2023.11.006_bib0061","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3324\/haematol.2010.030296","article-title":"Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma","volume":"96","author":"Hose","year":"2011","journal-title":"Haematologica"},{"issue":"17","key":"10.1016\/j.clml.2023.11.006_bib0062","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1182\/blood-2011-04-345801","article-title":"Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance","volume":"118","author":"Mateos","year":"2011","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.clml.2023.11.006_bib0063","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1182\/bloodadvances.2018024794","article-title":"Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma","volume":"2","author":"Aljama","year":"2018","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.clml.2023.11.006_bib0064","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.mayocp.2013.01.019","article-title":"Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines","volume":"88","author":"Mikhael","year":"2013","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2023.11.006_bib0065","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3109\/10428194.2011.628880","article-title":"Circulating endothelial progenitor cells as potential prognostic biomarker in multiple myeloma","volume":"53","author":"Bhaskar","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10.1016\/j.clml.2023.11.006_bib0066","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.leukres.2010.11.010","article-title":"Significantly reduced regulatory T cell population in patients with untreated multiple myeloma","volume":"35","author":"Gupta","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2023.11.006_bib0067","article-title":"Circulating regulatory T-cells in monoclonal gammopathies of uncertain significance and multiple myeloma: in search of a role","volume":"2016","author":"D'Arena","year":"2016","journal-title":"J Immunol Res"},{"issue":"9","key":"10.1016\/j.clml.2023.11.006_bib0068","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.1038\/bcj.2013.34","article-title":"Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg\/Th17 balance","volume":"3","author":"Bryant","year":"2013","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.clml.2023.11.006_bib0069","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00262-014-1646-4","article-title":"Tumor-induced CD14 +HLA-DR (-\/low) myeloid-derived suppressor cells correlate with tumor progression and outcome of therapy in multiple myeloma patients","volume":"64","author":"Wang","year":"2015","journal-title":"Cancer Immunol Immunother"},{"issue":"25","key":"10.1016\/j.clml.2023.11.006_bib0070","doi-asserted-by":"crossref","first-page":"37931","DOI":"10.18632\/oncotarget.9270","article-title":"Granulocytic myeloid-derived suppressor cells promote angiogenesis in the context of multiple myeloma","volume":"7","author":"Binsfeld","year":"2016","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.clml.2023.11.006_bib0071","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s00262-016-1861-2","article-title":"Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory\/relapsed multiple myeloma","volume":"65","author":"Lee","year":"2016","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"10.1016\/j.clml.2023.11.006_bib0072","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00432-018-2790-6","article-title":"Decitabine shows potent anti-myeloma activity by depleting monocytic myeloid-derived suppressor cells in the myeloma microenvironment","volume":"145","author":"Zhou","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.clml.2023.11.006_bib0073","doi-asserted-by":"crossref","DOI":"10.1038\/s43018-023-00657-1","article-title":"Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens. Nat Cancer","author":"Maura","year":"2023","journal-title":"Nat Cancer"},{"issue":"6","key":"10.1016\/j.clml.2023.11.006_bib0074","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1016\/j.clml.2023.11.006_bib0075","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","article-title":"The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients","volume":"41","author":"Friedrich","year":"2023","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.clml.2023.11.006_bib0076","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1158\/2643-3230.BCD-22-0018","article-title":"Changes in bone marrow tumor and immune cells correlate with durability of remissions following BCMA CAR T therapy in myeloma","volume":"3","author":"Dhodapkar","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"S1","key":"10.1016\/j.clml.2023.11.006_bib0077","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1182\/blood-2022-168903","article-title":"Differences in single cells between BCMA-targeting CAR T-cell therapy responders and non-responders reveals initial resistance and acquired resistance are driven by different factors","volume":"140","author":"Samur","year":"2022","journal-title":"Blood"},{"issue":"S1","key":"10.1016\/j.clml.2023.11.006_bib0078","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1182\/blood-2022-162709","article-title":"Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM): correlative analyses from majesTEC-1","volume":"140","author":"Cortes-Selva","year":"2022","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023021845?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023021845?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T19:35:16Z","timestamp":1709235316000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023021845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":78,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2152265023021845"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.11.006","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multiparametric Flow Cytometry in the Evaluation of Plasma Cell Proliferative Disorders: Current Paradigms for Clinical Practice","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}